Benitec Biopharma (BNTC) Earnings Analysis
Benitec Biopharma (BNTC) next reports earnings on 2026-09-28, consensus EPS -0.25 USD. Last quarter (2026-05-14) it beat with EPS -0.24 USD vs -0.27 USD est (+11.1%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -10.31.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BNTC next report earnings?
| Next earnings date | 2026-09-28 |
|---|---|
| Consensus EPS estimate | -0.25 USD |
| Revenue estimate | n/a |
BNTC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -0.24 USD | -0.27 USD | +11.1% | Beat |
| 2026-02-12 | -0.26 USD | -0.23 USD | -13% | Miss |
| 2025-11-14 | -0.22 USD | -0.35 USD | +37.1% | Beat |
| 2025-09-22 | -0.42 USD | -0.28 USD | -50% | Miss |
| 2025-05-14 | -0.24 USD | -0.36 USD | +33.3% | Beat |
| 2025-02-14 | -0.36 USD | -1 USD | +64% | Beat |
| 2024-11-14 | -0.48 USD | -0.61 USD | +21.3% | Beat |
Beat rate: 5/7 (71%) over reported quarters with consensus data.
BNTC valuation and analyst view
| Trailing P/E | -10.31 |
|---|---|
| Trailing EPS | -0.98983 USD |
| Price / book | 3.08 |
| Dividend yield | 0.00% |
| Market cap | 0.30B |
| Analyst consensus | Buy (6 buy / 1 hold / 0 sell) |
| Avg price target | 25 USD |
Related research pages
Frequently asked questions
When is Benitec Biopharma (BNTC)'s next earnings date?
Benitec Biopharma is next scheduled to report on 2026-09-28, with a consensus EPS estimate of -0.25 USD.
Did BNTC beat earnings last quarter?
In its 2026-05-14 report, BNTC posted EPS of -0.24 USD versus a -0.27 USD estimate — a beat of 11.1%.
What is BNTC's earnings track record?
Over the last 7 reported quarters with consensus data, BNTC beat estimates 5 times (71%).
What is BNTC's current P/E ratio and EPS?
BNTC trades at a trailing P/E of -10.31 on trailing EPS of -0.9898311072831414 USD.
What do analysts rate BNTC?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 25 USD.